Technical Analysis for ZNTL - Zentalis Pharmaceuticals, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Support | Bullish | 0.00% | |
Bollinger Band Squeeze | Range Contraction | 0.00% | |
Outside Day | Range Expansion | 0.00% | |
20 DMA Support | Bullish | 0.92% | |
Bollinger Band Squeeze | Range Contraction | 0.92% | |
NR7 | Range Contraction | 0.92% | |
BB Squeeze Started | Range Contraction | 0.92% | |
Inside Day | Range Contraction | 0.92% | |
Crossed Above 20 DMA | Bullish | 0.79% | |
Gapped Up | Strength | 0.79% |
Alert | Time |
---|---|
Rose Above Previous Day's High | 3 days ago |
Outside Day | 3 days ago |
Up 2% | 3 days ago |
10 DMA Resistance | 3 days ago |
Possible NR7 | 3 days ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/08/2024
Zentalis Pharmaceuticals LLC is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin Bunker on December 23, 2014 and is headquartered in New York, NY.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Drugs Breast Cancer Treatment Of Breast Cancer Tyrosine Kinase Receptors Epidermal Growth Factor Receptor Hormones Her2 Her2/Neu Transcription Factors Estrogen Molecule Therapeutics Antiestrogens Estrogen Receptor Receptor Positive Selective Estrogen Receptor Degraders Intracellular Receptors Metastatic Breast Cancer
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Drugs Breast Cancer Treatment Of Breast Cancer Tyrosine Kinase Receptors Epidermal Growth Factor Receptor Hormones Her2 Her2/Neu Transcription Factors Estrogen Molecule Therapeutics Antiestrogens Estrogen Receptor Receptor Positive Selective Estrogen Receptor Degraders Intracellular Receptors Metastatic Breast Cancer
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 31.46 |
52 Week Low | 9.56 |
Average Volume | 710,304 |
200-Day Moving Average | 16.08 |
50-Day Moving Average | 13.30 |
20-Day Moving Average | 11.85 |
10-Day Moving Average | 12.09 |
Average True Range | 0.94 |
RSI (14) | 46.52 |
ADX | 16.1 |
+DI | 13.15 |
-DI | 14.59 |
Chandelier Exit (Long, 3 ATRs) | 10.65 |
Chandelier Exit (Short, 3 ATRs) | 13.20 |
Upper Bollinger Bands | 12.99 |
Lower Bollinger Band | 10.71 |
Percent B (%b) | 0.6 |
BandWidth | 19.24 |
MACD Line | -0.33 |
MACD Signal Line | -0.44 |
MACD Histogram | 0.1121 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 13.03 | ||||
Resistance 3 (R3) | 12.99 | 12.62 | 12.87 | ||
Resistance 2 (R2) | 12.62 | 12.38 | 12.65 | 12.82 | |
Resistance 1 (R1) | 12.35 | 12.23 | 12.49 | 12.39 | 12.76 |
Pivot Point | 11.98 | 11.98 | 12.05 | 12.01 | 11.98 |
Support 1 (S1) | 11.71 | 11.74 | 11.85 | 11.75 | 11.38 |
Support 2 (S2) | 11.34 | 11.59 | 11.37 | 11.32 | |
Support 3 (S3) | 11.07 | 11.34 | 11.27 | ||
Support 4 (S4) | 11.11 |